U.S. Health Secretary Halts Enforcement on Six Unapproved Peptides
U. S. Health Secretary Robert F. Kennedy Jr. announced on October 28 in Washington, D.
C. , that the Department of Health and Human Services will cease enforcement against the sale of six compounded peptide drugs, despite FDA safety warnings. The announcement follows a temporary enforcement discretion the department granted earlier in the week, stating it would not pursue legal action against compounding pharmacies that produce the six peptides while a formal rule change is pending. Most FDA scientific staff had previously voiced opposition to the proposal, citing concerns about the compounds' safety.